DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Schmid P, Zaiss M, Harper-Wynne C. et al.
Abstract GS2-07: MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.
Cancer Res 2018;
78: GS2-07-GS02-07
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.